Alpha methylparatyrosine and tetrabenazine in movement disorders.
Clinical and experimental evidence suggests that alpha methylparatyrosine (AMPT), an inhibitor of tyrosine hydroxylase, can potentiate the effects of other dopamine antagonists. We therefore treated patients having various forms of dystonia and chorea with tetrabenazine (TBZ), and then added AMPT to determine if further improvement could be obtained. Side effects of both drugs were common, and they often necessitated withdrawal of the drug. Patients with Huntington's chorea and tardive dyskinesia were improved by TBZ. They obtained additional benefit from the combination of AMPT and TBZ. The results in the dystonia patients were disappointing with both drugs. Although a small number of patients did improve, and short- and long-term remissions occurred in a few, most patients with dystonia were not benefited by either drug.
D000328:Adult; D002819:Chorea / Q000188:drug therapy; D004359:Drug Therapy, Combination; D004421:Dystonia / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008781:Methyltyrosines / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy* / Q000503:physiopathology; D013747:Tetrabenazine / Q000009:adverse effects / Q000627:therapeutic use*; D014446:Tyrosine 3-Monooxygenase / Q000037:antagonists & inhibitors; D019805:alpha-Methyltyrosine
D008781:Methyltyrosines; D019805:alpha-Methyltyrosine; D014446:Tyrosine 3-Monooxygenase; D013747:Tetrabenazine